New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Appendix 4C - Quarterly and Business Update
- IMU presents new mimotope PD-1 vaccine data at AACR
- IMU presents new KEY-Vaxx and B-Vaxx data at AACR
- IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
- Imugene doses first patient in HER-Vaxx phase 2 trial
Later from Imugene
- Investor Presentation - Proposed Acquisition
- Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
- CF33 Oncolytic Virus Clinical Trial Program Update
- US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
- Imugene Receives $4.13 million R&D Tax Incentive
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene